This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sauna, Z. E. Articles by Gottesman, M. M. Search for Related Content PubMed PubMed Citation Articles by Sauna, Z. E. Articles by Gottesman, M. M. Related Collections Cellular Pathobiology Cellular Pathobiology: Cancer Genes and Genomics

Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer

¹ Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH and ² Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland

Requests for reprints: Michael M. Gottesman, Laboratory of Cell Biology, National Cancer Institute, NIH, 37 Convent Drive, Room 2108, Bethesda, MD 20892. Phone: 301-496-1530; Fax: 1-402-0450; E-mail: mgottesman{at}nih.gov.

Polymorphisms in the human genome contribute to wide variations in how individuals respond to medications, either by changing the pharmacokinetics of drugs or by altering the cellular response to therapeutic agents. The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an individual's genotype. Due to the relatively large frequency of single-nucleotide polymorphisms (SNP) in the human genome, synonymous SNPs are often disregarded in many pharmacogenomic studies based on the assumption that these are silent. We have shown recently that synonymous SNPs in ABCB1 (P-glycoprotein), which is implicated both in determining drug pharmacokinetics and multidrug resistance in human cancer cells, can affect protein conformation and function. We discuss the importance of polymorphisms in drug metabolizing enzymes and transporters in anticancer therapy and suggest that synonymous polymorphisms may play a more significant role than is currently assumed. [Cancer Res 2007;67(20):9609–12]

This article has been cited by other articles:

				Z. Jiang, X.-L. Wu, M. Zhang, J. J. Michal, and R. W. Wright Jr. The Complementary Neighborhood Patterns and Methylation-to-Mutation Likelihood Structures of 15,110 Single-Nucleotide Polymorphisms in the Bovine Genome Genetics, September 1, 2008; 180(1): 639 - 647. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Synonymous SNPs: Silent No More Cancer Reviews Online Content, November 1, 2007; 2007(8): 15 - 15. [Full Text] [PDF]